[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amyloid-pathology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amyloid-pathology":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":5},"100642202","using-light-therapy-for-mild-cognitive-impairment-100642202",false,"NCT07651787","Using Light Therapy for Mild Cognitive Impairment","Neurovascular and Mitochondrial Mechanisms of Transcranial Photobiomodulation in Vascular Mild Cognitive Impairment","LTMC","Inclusion Criteria:\n\n* Age: 55-95 years of age\n* Clinical Dementia Rating (CDR) equal to 0.5 and\u002For Montreal Cognitive Assessment (MoCA) \\\u003C26 and ≥19\n* Adequate hearing and visual acuity to participate in the examinations\n* English speaker\n* Presence of cerebrovascular pathology confirmed by structural brain imaging method\n\nExclusion Criteria:\n\n* Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer\n* Cerebrovascular accident other than TIA within 60 days prior to Visit 0\n* Diagnosis of amyloid angiopathy\n* Major psychiatric disease, including major depression not controlled on medications, alcohol or drug abuse\n* Neurodegenerative diseases, e.g: Parkinson's, any kind of dementia\n* Patients currently using commercial brain stimulation \u002F neuromodulation device as part of a research study\n* Patients currently take dietary supplements with an expected cerebrovascular benefit such as NAD- or NR-supplementum, L-citrullin, urolithin\n* Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, hypertension uncontrolled by medication (\\>160\u002F100 mmHg)\n* Any other medical condition or medication which, in the opinion of investigator, would render the patient too unstable to complete the study protocol\n* Severe sensory deficits interfering with the testing","ALL","55 Years","95 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in people with mild cognitive impairment (MCI). The main questions it aims to answer are:\n\n* Does tPBM enhance cognitive function and cerebral hemodynamic responses during memory and finger tapping tasks?\n* Does tPBM reduce oxidative stress, inflammation, and mitigate brain cell damage?\n* Is cognitive improvement linked to amyloid status, greater cerebral hemodynamic response, and lower levels of brain inflammation and oxidative stress? Researchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation.\n\nParticipants will:\n\n* Receive a 20-minute-long active tPBM or sham stimulation session once per day, 6 times per week, for 12 weeks.\n* Complete questionnaires and an iPad-based cognitive testing protocol.\n* Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG). Dynamic analysis of the vessels in the eye will also be performed based on eligibility. Transcranial Doppler (TCD) flowmetry is optionally performed.\n* Provide blood samples to test for biomarkers of inflammation, oxidative stress, and brain cell damage.",[28,29],"Mild Cognitive Impairment (MCI)","Amyloid Pathology",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Cognition","Neurovascular Coupling Mechanism and Cognitive Function","Neurovascular Control","Brain Aging","Brain Activity","Mild Congitive Impairment (MCI)","Amyloid","Transcranial photobiomodulation","Near-infrared spectroscopy","Cerebral hemodynamics","Near-infrared light therapy","NIH Toolbox Cognition Battery","Electroencephalography","Amyloid-positive mild cognitive impairment","Amyloid-negative mild cognitive impairment","Extracellular vesicles","Neuroinflammation","Proinflammatory cytokines","Home-based neuromodulation","Non-invasive brain stimulation","Sham-controlled clinical trial","Randomized clinical trial","photobiomodulation therapy","RECRUITING","2026-06-10",{"date":57,"type":58},"2026-06-16","ACTUAL",{"date":60,"type":58},"2025-10-01",{"date":62,"type":22},"2026-12-31",{"name":64,"class":65},"University of Oklahoma","OTHER"]